CN102018699A - Xyloketal B在制备抗动脉粥样硬化药物中的应用 - Google Patents
Xyloketal B在制备抗动脉粥样硬化药物中的应用 Download PDFInfo
- Publication number
- CN102018699A CN102018699A CN2010105865974A CN201010586597A CN102018699A CN 102018699 A CN102018699 A CN 102018699A CN 2010105865974 A CN2010105865974 A CN 2010105865974A CN 201010586597 A CN201010586597 A CN 201010586597A CN 102018699 A CN102018699 A CN 102018699A
- Authority
- CN
- China
- Prior art keywords
- xyloketal
- ldl
- group
- simvastatin
- atherosclerosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 230000000879 anti-atherosclerotic effect Effects 0.000 title claims abstract description 9
- CCNANHBVUNZCKA-FCOFOHSNSA-N (4R,7R,8R,15R,18R,19R)-4,7,15,18-tetramethyl-3,5,14,16-tetraoxapentacyclo[11.7.0.02,10.04,8.015,19]icosa-1(13),2(10),11-trien-11-ol Chemical compound O1[C@@]2(C)OC[C@H](C)[C@H]2CC2=C1C=C(O)C1=C2O[C@@]2(C)OC[C@H](C)[C@H]2C1 CCNANHBVUNZCKA-FCOFOHSNSA-N 0.000 title abstract description 66
- CCNANHBVUNZCKA-UHFFFAOYSA-N xyloketal B Natural products O1C2(C)OCC(C)C2CC2=C1C=C(O)C1=C2OC2(C)OCC(C)C2C1 CCNANHBVUNZCKA-UHFFFAOYSA-N 0.000 title abstract description 63
- 108010028554 LDL Cholesterol Proteins 0.000 claims abstract description 47
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 37
- 210000004369 blood Anatomy 0.000 claims abstract description 13
- 239000008280 blood Substances 0.000 claims abstract description 13
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims description 18
- 150000002632 lipids Chemical class 0.000 claims description 15
- 210000003038 endothelium Anatomy 0.000 claims description 14
- 210000004204 blood vessel Anatomy 0.000 claims description 12
- 230000003064 anti-oxidating effect Effects 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000033228 biological regulation Effects 0.000 claims description 5
- 108010023302 HDL Cholesterol Proteins 0.000 claims description 3
- 230000000630 rising effect Effects 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 2
- 229930182970 xyloketal Natural products 0.000 claims description 2
- 238000002474 experimental method Methods 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 16
- 230000007246 mechanism Effects 0.000 abstract description 6
- 230000036542 oxidative stress Effects 0.000 abstract description 5
- 230000009471 action Effects 0.000 abstract description 4
- 230000003143 atherosclerotic effect Effects 0.000 abstract description 3
- 231100000252 nontoxic Toxicity 0.000 abstract description 3
- 230000003000 nontoxic effect Effects 0.000 abstract description 3
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- 230000003902 lesion Effects 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract 2
- 210000003989 endothelium vascular Anatomy 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 30
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 30
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 30
- 229960002855 simvastatin Drugs 0.000 description 30
- 210000002966 serum Anatomy 0.000 description 25
- 102000013918 Apolipoproteins E Human genes 0.000 description 19
- 108010025628 Apolipoproteins E Proteins 0.000 description 19
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 17
- 238000000034 method Methods 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 12
- 210000000709 aorta Anatomy 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 210000002540 macrophage Anatomy 0.000 description 11
- 210000002381 plasma Anatomy 0.000 description 11
- 235000012000 cholesterol Nutrition 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 238000004043 dyeing Methods 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 210000003291 sinus of valsalva Anatomy 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 6
- 230000035882 stress Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000010166 immunofluorescence Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 238000004445 quantitative analysis Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000000853 LDL receptors Human genes 0.000 description 4
- 108010001831 LDL receptors Proteins 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 210000004026 tunica intima Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 238000013258 ApoE Receptor knockout mouse model Methods 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 230000008753 endothelial function Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000000497 foam cell Anatomy 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 208000000501 Lipidoses Diseases 0.000 description 2
- 206010024585 Lipidosis Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000003725 endotheliocyte Anatomy 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 238000000556 factor analysis Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000010413 mother solution Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- 206010065558 Aortic arteriosclerosis Diseases 0.000 description 1
- 101100046775 Arabidopsis thaliana TPPA gene Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 244000050510 Cunninghamia lanceolata Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000016610 Oxidized LDL Receptors Human genes 0.000 description 1
- 108010028191 Oxidized LDL Receptors Proteins 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- JPYHHZQJCSQRJY-UHFFFAOYSA-N Phloroglucinol Natural products CCC=CCC=CCC=CCC=CCCCCC(=O)C1=C(O)C=C(O)C=C1O JPYHHZQJCSQRJY-UHFFFAOYSA-N 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 240000002044 Rhizophora apiculata Species 0.000 description 1
- 208000013200 Stress disease Diseases 0.000 description 1
- 239000000524 Thiobarbituric Acid Reactive Substance Substances 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- YVNQAIFQFWTPLQ-UHFFFAOYSA-O [4-[[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfophenyl)methyl]amino]-2-methylphenyl]methylidene]-3-methylcyclohexa-2,5-dien-1-ylidene]-ethyl-[(3-sulfophenyl)methyl]azanium Chemical compound C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=C1 YVNQAIFQFWTPLQ-UHFFFAOYSA-O 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 201000001962 aortic atherosclerosis Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000012155 injection solvent Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- QCDYQQDYXPDABM-UHFFFAOYSA-N phloroglucinol Chemical compound OC1=CC(O)=CC(O)=C1 QCDYQQDYXPDABM-UHFFFAOYSA-N 0.000 description 1
- 229960001553 phloroglucinol Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- XZZNDPSIHUTMOC-UHFFFAOYSA-N triphenyl phosphate Chemical compound C=1C=CC=CC=1OP(OC=1C=CC=CC=1)(=O)OC1=CC=CC=C1 XZZNDPSIHUTMOC-UHFFFAOYSA-N 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010586597.4A CN102018699B (zh) | 2010-12-14 | 2010-12-14 | Xyloketal B在制备调节血脂水平药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010586597.4A CN102018699B (zh) | 2010-12-14 | 2010-12-14 | Xyloketal B在制备调节血脂水平药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102018699A true CN102018699A (zh) | 2011-04-20 |
CN102018699B CN102018699B (zh) | 2014-03-26 |
Family
ID=43860751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201010586597.4A Expired - Fee Related CN102018699B (zh) | 2010-12-14 | 2010-12-14 | Xyloketal B在制备调节血脂水平药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102018699B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103027908A (zh) * | 2012-11-19 | 2013-04-10 | 何晓涛 | Aphanamixoid A在制备治疗动脉粥样硬化药物中的应用 |
CN103833840A (zh) * | 2012-11-27 | 2014-06-04 | 上海复星医药(集团)股份有限公司 | 一种从人血浆中提取高密度脂蛋白及分离纯化载脂蛋白apoA-I的方法 |
WO2022088550A1 (zh) * | 2020-10-27 | 2022-05-05 | 美康生物科技股份有限公司 | 一种用于检测脂蛋白颗粒浓度的试剂及其使用方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101580512A (zh) * | 2008-05-15 | 2009-11-18 | 中山大学 | 南海真菌中新鹿角缩酮类化合物及其在制备抗高血压药物中的应用 |
CN101580511A (zh) * | 2008-05-15 | 2009-11-18 | 中山大学 | 南海真菌中新鹿角缩酮类化合物在制备胞内抗氧化应激药物中的应用 |
CN101747351A (zh) * | 2009-12-18 | 2010-06-23 | 中山大学 | Xyloketals类化合物的合成方法 |
-
2010
- 2010-12-14 CN CN201010586597.4A patent/CN102018699B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101580512A (zh) * | 2008-05-15 | 2009-11-18 | 中山大学 | 南海真菌中新鹿角缩酮类化合物及其在制备抗高血压药物中的应用 |
CN101580511A (zh) * | 2008-05-15 | 2009-11-18 | 中山大学 | 南海真菌中新鹿角缩酮类化合物在制备胞内抗氧化应激药物中的应用 |
CN101747351A (zh) * | 2009-12-18 | 2010-06-23 | 中山大学 | Xyloketals类化合物的合成方法 |
Non-Patent Citations (3)
Title |
---|
YAN QIAN ET AL: "Anti-Apoptosis Effects of Xyloketal B in Rat Aortic Smooth Muscle Cells", 《ABSTRACTS OF THE 3RD CHINA-RUSSIA INTERNATIONAL SYMPOSIUM ON PHARMACOLOGY》 * |
YAN QIAN ET AL: "Anti-Apoptosis Effects of Xyloketal B in Rat Aortic Smooth Muscle Cells", 《ABSTRACTS OF THE 3RD CHINA-RUSSIA INTERNATIONAL SYMPOSIUM ON PHARMACOLOGY》, 31 December 2008 (2008-12-31), pages 32 - 33 * |
杜凤鸣 等: "脂蛋白代谢与动脉粥样硬化的关系", 《第二军医大学学报》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103027908A (zh) * | 2012-11-19 | 2013-04-10 | 何晓涛 | Aphanamixoid A在制备治疗动脉粥样硬化药物中的应用 |
CN103833840A (zh) * | 2012-11-27 | 2014-06-04 | 上海复星医药(集团)股份有限公司 | 一种从人血浆中提取高密度脂蛋白及分离纯化载脂蛋白apoA-I的方法 |
WO2022088550A1 (zh) * | 2020-10-27 | 2022-05-05 | 美康生物科技股份有限公司 | 一种用于检测脂蛋白颗粒浓度的试剂及其使用方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102018699B (zh) | 2014-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101740893B1 (ko) | Akkermansia muciniphila 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물 | |
CN101507729B (zh) | 人参皂苷Compound K在制备防治动脉粥样硬化的药物中的应用 | |
CN102018699B (zh) | Xyloketal B在制备调节血脂水平药物中的应用 | |
US9532967B2 (en) | Use of phenethyl caffeate derivatives in the preparation of a medicament against tumor angiogenesis | |
Guo et al. | Human TFF2-Fc fusion protein alleviates DSS-induced ulcerative colitis in C57BL/6 mice by promoting intestinal epithelial cells repair and inhibiting macrophage inflammation | |
CN107213145A (zh) | 细锥香茶菜乙素在制备抑制食管鳞癌细胞增殖的产品中的应用 | |
CN105012356B (zh) | 灵芝酸a在抗抑郁症中的用途 | |
CN110538170B (zh) | 玛咖酰胺类化合物或其盐在制备预防或治疗肝纤维化疾病药物的应用 | |
CN109913407B (zh) | 脂肪来源间充质干细胞类外泌体的制备方法及应用 | |
CN105796581A (zh) | 芍药苷在制备调控胆碱能抗炎通路药物中的应用 | |
CN109223735A (zh) | 从杂色曲霉次级代谢物中分离出的活性化合物的用途 | |
CN101947232B (zh) | 仙人掌果多糖在制备药物或保健品中的应用 | |
CN104784192A (zh) | 蚌肉寡糖在制备降血糖药物中的应用及其制备方法 | |
CN115944631B (zh) | 裸花酸及其衍生物在制备肿瘤免疫治疗增效剂中的应用 | |
CN102028674A (zh) | 针叶聚戊烯醇在制备预防和/或治疗阿尔茨海默病的药物中的应用 | |
CN101966221B (zh) | 仙人掌果在制备药物或保健品中的应用 | |
CN115350185B (zh) | 多潘立酮在制备治疗溃疡性结肠炎药物中的应用 | |
CN102397287B (zh) | 仙人掌果多糖在制备降血脂作用的药物或保健品中的应用 | |
CN101524386A (zh) | 用于治疗脂肪肝的中药主要成分组方 | |
CN105395808A (zh) | 一种用于治疗糖尿病的增效药物组合物 | |
CN1857351A (zh) | 一种抗肿瘤的药物组合物及其制备方法 | |
CN118178574A (zh) | 一种酒糟醇提物抗肿瘤活性组分的制备方法和应用 | |
CN1709444A (zh) | 一种止痛的藏药药物及其制备方法 | |
CN104341405B (zh) | 一种具有抑制Aβ聚集活性的化合物的制备方法与用途 | |
CN102397286B (zh) | 仙人掌果多糖在制备降血糖作用的药物或保健品中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Wang Guanlei Inventor after: Li Jie Inventor after: Pang Jiyan Inventor after: Lin Yongcheng Inventor after: Liu Jie Inventor after: Xie Yu Inventor before: Wang Guanlei Inventor before: Pang Jiyan Inventor before: Lin Yongcheng Inventor before: Liu Jie Inventor before: Xie Yu Inventor before: Liu Canzhao |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: WANG GUANLEI PANG JIYAN LIN YONGCHENG LIU JIE JIE YU LIU CANZHAO TO: WANG GUANLEI LI JIE PANG JIYAN LIN YONGCHENG LIU JIE JIE YU |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140326 |